Tocilizumab plus glucocorticoids in severe and critically COVID-19 patients. A single center experience

Gustavo Jiménez-Brítez; Pablo Ruíz; Xavier Soler

doi:10.1016/j.medcli.2020.07.001

ScienceGate Book Chapters

JOURNAL ARTICLE

Tocilizumab plus glucocorticoids in severe and critically COVID-19 patients. A single center experience

Gustavo Jiménez-Brítez Pablo Ruíz Xavier Soler

Year: 2020 Journal: Medicina Clínica Vol: 155 (9)Pages: 410-411 Publisher: Elsevier BV

DOI: 10.1016/j.medcli.2020.07.001

Get Full-Text PDF Get Analytical Report

Keywords:

Coronavirus disease 2019 (COVID-19) Critically ill Tocilizumab Single Center Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 2019-20 coronavirus outbreak Medicine Center (category theory) Virology Intensive care medicine Internal medicine Chemistry

Metrics

Cited By

0.26

FWCI (Field Weighted Citation Impact)

Refs

0.67

Citation Normalized Percentile

Is in top 1%

Is in top 10%

Citation History

Topics

COVID-19 Clinical Research Studies

Health Sciences → Medicine → Infectious Diseases

Long-Term Effects of COVID-19

Health Sciences → Medicine → Neurology

COVID-19 Impact on Reproduction

Health Sciences → Medicine → Obstetrics and Gynecology

Tocilizumab plus glucocorticoids in severe and critically COVID-19 patients. A single center experience

Metrics

Citation History

Topics

Related Documents

Tocilizumab plus glucocorticoids in severe and critically COVID-19 patients. A single center experience

TOCILIZUMAB USE IN SEVERE COVID-19: A SINGLE CENTER EXPERIENCE

Tocilizumab in patients with severe COVID‐19: A single‐center observational analysis

Efficacy of Tocilizumab in COVID‐19: Single‐Center Experience

Tocilizumab treatment in COVID‐19: A single center experience